RecruitingPHASE1, PHASE2NCT06907875
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Epicrispr Biotechnologies, Inc.
- Intervention
- EPI-321(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2032
Study locations (7)
- David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
- Rare Disease Research, Atlanta, Georgia, United States
- Kennedy Krieger Institute, Center for Genetic Muscle Disorders, Baltimore, Maryland, United States
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
- Utah Program for Inherited Neuromuscular Disorders - University of Utah, Salt Lake City, Utah, United States
- Royal Alfred Hospital, Sydney, New South Wales, Australia
- Pacific Clinical Research Network, Auckland, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06907875 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07086521Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)Restem, LLC.
- RECRUITINGPHASE3NCT07038200A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDAvidity Biosciences, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon
- ACTIVE NOT RECRUITINGPHASE2NCT06222827Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1Centre Hospitalier Universitaire de Nice